Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
DXR Stock Forecast 2025-2026
$9.00
Current Price
$44.66M
Market Cap
Buy 2
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to DXR Price Targets
+177.8%
To High Target of $25.00
+161.1%
To Median Target of $23.50
+144.4%
To Low Target of $22.00
DXR Price Momentum
+2.4%
1 Week Change
+17.2%
1 Month Change
+1.9%
1 Year Change
+17.0%
Year-to-Date Change
-9.9%
From 52W High of $9.99
+37.4%
From 52W Low of $6.55
📊 TOP ANALYST CALLS
Did DXR Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Daxor is one of their latest high-conviction picks.
Latest DXR Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, DXR has a bullish consensus with a median price target of $23.50 (ranging from $22.00 to $25.00). Currently trading at $9.00, the median forecast implies a 161.1% upside. This outlook is supported by 2 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Edward Woo at Ascendiant Capital, projecting a 177.8% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
DXR Analyst Ratings
2
Buy
0
Hold
0
Sell
DXR Price Target Range
Low
$22.00
Average
$23.50
High
$25.00
Current: $9.00
Latest DXR Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for DXR.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 17, 2025 | Ascendiant Capital | Edward Woo | Buy | Maintains | $25.00 |
| Sep 9, 2024 | Ascendiant Capital | Edward Woo | Buy | Maintains | $24.75 |
| Mar 25, 2021 | Ascendiant Capital | Edward Woo | Buy | Assumes | $21.00 |
| Jul 29, 2019 | Maxim Group | Buy | Initiates | $22.00 | |
| May 16, 2019 | Ascendiant | Buy | Initiates | $0.00 | |
| May 16, 2019 | Ascendiant Capital | Buy | Initiates | $0.00 |
Daxor Corporation (DXR) Competitors
The following stocks are similar to Daxor based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Daxor Corporation (DXR) Financial Data
Daxor Corporation has a market capitalization of $44.66M with a P/E ratio of 6.6x. The company generates $119,714 in trailing twelve-month revenue with a 448.0% profit margin.
Revenue growth is -41.8% quarter-over-quarter, while maintaining an operating margin of -2,368.7% and return on equity of +1.5%.
Valuation Metrics
Market Cap
$44.66M
Enterprise Value
$0
P/E Ratio
6.6x
PEG Ratio
0.0x
Price/Sales
373.1x
Growth & Margins
Revenue Growth (YoY)
-41.8%
Gross Margin
N/A
Operating Margin
-2,368.7%
Net Margin
+448.0%
EPS Growth
-34.7%
Financial Health
Cash/Price Ratio
0.0%
Current Ratio
0.2x
Debt/Equity
2.0x
ROE
+1.5%
ROA
-2.5%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Daxor Corporation (DXR) Business Model
About Daxor Corporation
What They Do
Medical instrumentation and biotechnology for blood analysis.
Business Model
The company generates revenue primarily through the sale of its Blood Volume Analyzer (BVA-100), a diagnostic tool that aids healthcare professionals in managing patients' blood volume. By offering innovative solutions for fluid management in critical care, Daxor not only enhances patient outcomes but also positions itself as a key player in the biomedical devices market.
Additional Information
Headquartered in New York, Daxor is committed to ongoing research and development to expand its technology's applications. Its focus on improving diagnostic accuracy is critical in healthcare, attracting interest from investors looking for advancements in medical technologies.
Company Information
Sector
Healthcare
Industry
Medical Instruments & Supplies
Employees
0
CEO
Mr. Michael Richard Feldschuh
Country
United States
IPO Year
1992
Website
www.daxor.comDaxor Corporation (DXR) Latest News & Analysis
Latest News
Quick Summary
Daxor Corporation (Nasdaq: DXR) reports new research from Duke University highlighting Blood Volume Analysis (BVA) as an effective method for identifying anemia in heart failure patients.
Why It Matters
Daxor Corporation's new research highlights its BVA technology's effectiveness in diagnosing anemia in heart failure patients, potentially increasing demand for its products and boosting revenue.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Daxor Corporation (Nasdaq: DXR) expands its blood volume measurement technology into East Tennessee and the Pacific Northwest, enhancing care for cardiovascular and critical care patients.
Why It Matters
Daxor's expansion into East Tennessee and the Pacific Northwest enhances its market position, potentially increasing revenue from new healthcare partnerships and solidifying its leadership in blood measurement technology.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Three New Medical Centers Adopt Daxor's Blood Volume Diagnostic Signaling Growing Clinical Acceptance
1 month ago
Quick Summary
Daxor Corporation (Nasdaq: DXR) expands its blood volume analysis services to three new hospitals, enhancing accessibility and operational efficiency with its CLIA-certified ezBVA Lab service.
Why It Matters
Daxor's expansion and new lab service enhance its market position, potentially increasing revenue and investor confidence as demand for efficient healthcare solutions rises.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Daxor Corporation (Nasdaq: DXR) launched a new BVA program at a Florida healthcare center, enhancing fluid management and treatment outcomes in inpatient and outpatient care.
Why It Matters
Daxor's expansion in Florida enhances its market position in blood volume analysis, potentially increasing revenue and improving treatment outcomes, which could positively influence stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Daxor Corporation (Nasdaq: DXR) will showcase its blood volume analysis technology at the ISHLT Annual Meeting, attended by 3,500 specialists in heart and lung disease.
Why It Matters
Daxor's presence at a major medical conference highlights its leadership in blood volume technology, potentially leading to increased partnerships, sales, and market credibility in a specialized healthcare sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Daxor Corporation to Showcase Innovative Blood Volume Analysis at MedAxiom Cardiovascular Transforum Spring 2025
2 months ago
Quick Summary
WellStar Health System is set to unveil a new strategy aimed at significantly reducing kidney injury after LVAD implantation, driven by BVA insights.
Why It Matters
WellStar's new strategy could enhance patient outcomes and reduce healthcare costs, potentially boosting its market position and attracting investor interest in the healthcare sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About DXR Stock
What is Daxor Corporation's (DXR) stock forecast for 2025?
Based on our analysis of 2 Wall Street analysts, Daxor Corporation (DXR) has a median price target of $23.50. The highest price target is $25.00 and the lowest is $22.00.
Is DXR stock a good investment in 2025?
According to current analyst ratings, DXR has 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $9.00. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for DXR stock?
Wall Street analysts predict DXR stock could reach $23.50 in the next 12 months. This represents a 161.1% increase from the current price of $9.00. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Daxor Corporation's business model?
The company generates revenue primarily through the sale of its Blood Volume Analyzer (BVA-100), a diagnostic tool that aids healthcare professionals in managing patients' blood volume. By offering innovative solutions for fluid management in critical care, Daxor not only enhances patient outcomes but also positions itself as a key player in the biomedical devices market.
What is the highest forecasted price for DXR Daxor Corporation?
The highest price target for DXR is $25.00 from Edward Woo at Ascendiant Capital, which represents a 177.8% increase from the current price of $9.00.
What is the lowest forecasted price for DXR Daxor Corporation?
Price targets from Wall Street analysts for DXR are not currently available. The stock is trading at $9.00.
What is the overall DXR consensus from analysts for Daxor Corporation?
The overall analyst consensus for DXR is bullish. Out of 2 Wall Street analysts, 2 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $23.50.
How accurate are DXR stock price projections?
Stock price projections, including those for Daxor Corporation, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 19, 2025 2:55 AM UTC